Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy

Quan Zhou, Chengyuan Dong, Wufa Fan, Haiping Jiang, Jiajia Xiang, Nasha Qiu, Ying Piao, Tao Xie, Yingwu Luo, Zichen Li, Fusheng Liu, Youqing Shen
2020-05-01
Abstract:Nanotechnology-based drug delivery platforms have been explored for cancer treatments and resulted in several nanomedicines in clinical uses and many in clinical trials. However, current nanomedicines have not met the expected clinical therapeutic efficacy. Thus, improving therapeutic efficacy is the foremost pressing task of nanomedicine research. An effective nanomedicine must overcome biological barriers to go through at least five steps to deliver an effective drug into the cytosol of all the cancer cells in a tumor. Of these barriers, nanomedicine extravasation into and infiltration throughout the tumor are the two main unsolved blockages. Up to now, almost all the nanomedicines are designed to rely on the high permeability of tumor blood vessels to extravasate into tumor interstitium, i.e., the enhanced permeability and retention (EPR) effect or so-called “passive tumor accumulation”; however, the EPR …
What problem does this paper attempt to address?